Binding of the epoxide cryptophycin analog, LY355703 to albumin and its effect on in vitro antiproliferative activity

Oncology Reports

Volumn 5, Issue 5, 1998, Pages 1089-1094

  Schultz, Richard M ^a   Shih, Chuan ^a   Wood, Paul G ^a   Harrison, Steadman D ^a   Ehlhardt, William J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Albumin; Cryptophycins; LY355703; Tumor cytotoxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CRYPTOPHYCIN 52; LY 335703; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY TEST; DOG; DRUG ACCUMULATION; DRUG DETERMINATION; DRUG POTENCY; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NOSTOC; PLASMA; PRIORITY JOURNAL; RAT;

EID: 0031857622     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.5.1089     Document Type: Article

References (19)

1. Smith CD, Zhang X, Mooberry SL, Patterson GML and Moore RE: Cryptophycin: a new antimicrotubule agent active against drug-resistant cells. Cancer Res 54: 3779-3784, 1994.
2. Endicott JA and Ling V: The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137-171, 1989.
3. Moscow JA and Cowan KH: Multidrug resistance. J Natl Cancer Inst 80: 14-20, 1988.
4. Corbett TH, Valeriote FA, Demchik L, Polin L, Panchapor C, Pugh S, White K, Knight J, Jones J, Jones L, LoRusso P, Foster B, Wiegand RA, Lisow L, Golakoti T, Heltzel CE, Ogino J, Patterson GML and Moore RE: Preclinical anticancer activity of cryptophycin-8. J Exp Ther Oncol 1: 95-108, 1996.
5. Hamel E: Antimitotic natural products and their interactions with tubulin. Med Res Rev 16: 207-231, 1996.
6. Kerksiek K, Mejillano MR, Schwartz RE, Georg GI and Himes RH: Interaction of cryptophycin 1 with tubulin and microbubules. FEBS Lett 377: 59-61, 1995.
7. Smith CD and Zhang X: Mechanism of action of cryptophycin. J Biol Chem 271: 6192-6198, 1996.
8. Bai R, Schwartz RE, Kepler JA, Pettit GR and Hamel E: Characterization of the interaction of cryptophycin 1 with tubulin: binding in the vinca domain, competitive inhibition of dolastatin 10 binding, and an unusual aggregation reaction. Cancer Res 56: 4398-4406, 1996.
9. Mooberry SL, Taoka CR and Busquets L: Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site the may overlap the vinca binding site. Cancer Lett 107: 53-57, 1996.
10. Ovejera AA and Houchens DP: Human tumor xenografts in athymic nude mice as a preclinical screen for anticancer agents. Semin Oncol 8: 386-393, 1981.
11. Houghton JA and Taylor DM: Growth characteristics of human colorectal tumours during serial passage in immune-deprived mice. Br J Cancer 37: 213-223, 1978.
12. Mooberry SL, Busquets L and Tien G: Induction of apoptosis by Cryptophycin 1, a new antimicrotubule agent. Int J Cancer 73: 440-448, 1997.
13. Song D, Hsu L-F and Au JL: Binding of taxol to plastic and glass containers and protein under in vitro conditions. J Pharm Sci 85: 29-31, 1996.
14. 1-acid glycoprotein. Res Commun Chem Pathol Pharmacol 80: 337-344, 1993.
15. Vyas D: Paclitaxel formulation and prodrugs. In: The Chemistry and Pharmacology of Taxol and its Derivatives. Farma V (ed). Elsevier Science, New York. pp 103-130, 1995.
16. Sparreboom A, van Tellingen O, Nooijen WJ and Beijnen JH: Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56: 2112-2115, 1996.
17. Gibaldi M: In: Biopharmaceutics and Clinical Pharmacokinetics. 3rd edition. Lea and Febiger, Philadelphia, pp 168-180, 1984.
18. Burke TG and Mi Z: The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 37: 40-46, 1994.
19. Mi Z, Malak H and Burke TG: Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry 34: 13722-13728, 1995.